04 Nov Issue of Options
Galileo Resources Plc
(“Galileo” or the “Company”)
Issuance of Director & Employee share options
Galileo, the exploration and development mining company, announces that options to subscribe for 23,600,000 new ordinary shares of the Company (“Ordinary Shares”) in two tranches of 11,800,000 Ordinary Shares each were granted on 3 November 2020 to the directors of the Company and key officers and employees (the “Options”). The first tranche of Options have an exercise price of 1.45 pence and vest immediately whilst the second tranche have an exercise price of 1.85 pence and vest on 1 March 2021. The Options have a term of five years and any unexercised options will expire at midnight 3 November 2025 and in aggregate represent approximately 2.89% of the Company’s issued share capital.
The Options announced today will result in a net increase of 23,600,000 options held by Directors, officers, and employees of the Company. Subsequent to this grant, a total of 68,400,000 share options are held by the Company’s current Directors, officers and employees representing approximately 8.37% of the share capital outstanding Ordinary Shares). All outstanding options held by current Directors, officers, and employees, other than those included in this grant, have exercise prices ranging between 1.45 and 1.85 pence per share.
The Board approved the issuance of the Options to incentivise and retain key Directors, officers and employees critical to enhancing the future market value of the Company and notes the significant premium of the respective exercise prices relative to the current share price. The Board considered both historical practices and on-going funding requirements in this regard
The Option exercise prices in the two tranches are at approximately 86% and 137% premiums respectively to the closing mid-market price as at 3 November 2020.
The grants made to the directors and PDMR’s are as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Following the implementation of the above option grant, the directors will hold the following options over Ordinary Shares:
| Director | Number of Ordinary Shares to which the options relate | Option exercise price
pence |
| Colin Bird | 5,000,000 | 1.85 |
| 7,500,000 | 1.30 | |
| 7,500,000 | 1.80 | |
| 3,500,000 | 1.85 | |
| 3,500,000 | 1.45 | |
| Joel Silberstein | 1,000,000 | 1.85 |
| 1,000,000 | 1.45 | |
| Edward Slowey | 500,000 | 1.30 |
| 500,000 | 1.80 | |
| 1,500,000
1,500,000 |
1.85
1.45 |
|
| Richard Wollenberg | 750,000
750,000 750,000 |
1.85
1.30 1.80 |
| 500,000 | 1.85 | |
| 500,000 | 1.45 | |
| Christopher Molefe | 250,000
500,000 500.000 |
1.85
1.30 1.80 |
| 300,000 | 1.85 | |
| 300,000 | 1.45 | |
A copy of this announcement is available on the Company’s website www.galileoresources.com.
You can also follow Galileo on Twitter: @GalileoResource.
You can also follow Galileo on Twitter: @GalileoResource
For further information, please contact: Galileo Resources PLC
| Colin Bird, Chairman
Edward Slowey, Executive Director |
Tel +44 (0) 20 7581 4477
Tel +353 (0) 601 4466
|
| Beaumont Cornish Limited – Nomad
Roland Cornish/James Biddle |
Tel +44 (0) 20 7628 3396 |
| Novum Securities Limited – Joint Broker
Colin Rowbury /Jon Belliss |
+44 (0) 20 7399 9400 |
| Shard Capital Partners LLP – Joint Broker
Damon Heath |
Tel +44 (0) 20 7186 9952 |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END